![]() |
市場調查報告書
商品編碼
2095538
無需散瞳的手持式眼底攝影機市場-2026-2032年全球市場預測Nonmydriatic Handheld Fundus Cameras Market - Global Forecast 2026-2032 |
||||||
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
預計到 2032 年,非散瞳手持式眼底攝影機市場將成長至 1.6418 億美元,複合年成長率為 5.99%。
| 主要市場統計數據 | |
|---|---|
| 基準年 2025 | 1.092億美元 |
| 預計年份:2026年 | 1.1864億美元 |
| 預測年份 2032 | 1.6418億美元 |
| 複合年成長率 (%) | 5.99% |
無需散瞳的手持式眼底攝影機正在革新眼底成像技術,無需常規藥物散瞳即可拍攝高品質的眼底照片。這使得在基層醫療、內分泌科診所、流動醫療計畫、急診、藥房和社區服務機構等場所能夠更快地進行眼科檢查。隨著糖尿病、高血壓、青光眼、老齡化黃斑部病變以及可預防性視力喪失等疾病在全球範圍內的負擔不斷加重,這些攜帶式眼底攝影機的重要性日益凸顯,其中糖尿病是主要致病因素之一。根據國際糖尿病聯盟(IDF)統計,2021年全球有5.37億成年人患有糖尿病,糖尿病視網膜病變仍是工作年齡層成年人視力喪失的主要原因。世界衛生組織(WHO)也將未經治療的屈光不正、白內障、青光眼、糖尿病視網膜病變和老齡化黃斑部病變列為視力喪失的主要原因。手持式非散瞳眼底攝影機有助於滿足這些臨床需求,改善視網膜檢查的可及性,即使在難以充分實施桌上型眼底攝影機、散瞳檢查或與眼科醫師會診的環境中也是如此。
非散瞳手持式眼底攝影機的發展趨勢正從以設備為中心的部署模式轉向整合式視網膜篩檢生態系統。傳統上,眼底攝影主要集中在眼科診所和醫院眼科,這些機構配備有訓練有素的放射科醫生和固定設備。如今,社區診所、藥局、糖尿病中心、行動篩檢車、地方健康中心,甚至家庭訪視模式,都擴大採用這種設備。這種轉變反映了更廣泛的醫療保健趨勢,例如疾病早期檢測、分散式診斷、價值醫療、慢性病管理以及利用連網型設備來彌合專科醫療服務缺口。
人工智慧正透過提高篩檢的擴充性、分診的一致性和工作流程的效率,對非散瞳手持式眼底攝影機的使用產生累積影響。基於人工智慧的視網膜影像分析已被廣泛研究用於檢測糖尿病視網膜病變,多項同行評審評估表明,當影像品質良好且演算法針對目標族群進行檢驗時,該方法可提供較高的診斷效能。獲得監管機構批准的用於糖尿病視網膜病變篩檢的自主或輔助人工智慧系統已證明,視網膜成像診斷可以在專業眼科診所之外實施,並且正在進行的研究正在擴展人工智慧的應用範圍,使其涵蓋青光眼風險評估、黃斑疾病檢測、高血壓性視網膜病變、心血管風險標誌物和影像品質評估等領域。
亞太地區是無需散瞳的手持式眼底攝影機最重要的應用區域之一,這得益於該地區糖尿病患者數量眾多、都市區醫療體系較為發達,以及農村地區醫療服務獲取方面持續存在的差距。儘管中國和印度的糖尿病和視網膜疾病負擔尤其沉重,但日本、韓國、澳洲和新加坡在數位醫療基礎設施、老年護理模式和遠距眼科診療能力方面正在取得進展。公共篩檢措施、醫院現代化和慢性病防治計畫的擴展正在推動這項技術的應用,但其實施品質將取決於保險報銷、醫護人員培訓、通訊基礎設施和當地服務提供能力。
在東南亞國協,隨著各國政府擴大全民健康覆蓋(UHC)、糖尿病照護和社區篩檢的範圍,無需散瞳的手持式眼底攝影機的重要性日益凸顯。新加坡、馬來西亞、泰國、印尼、越南和菲律賓的都市區醫院正在加強其數位化診斷系統,而攜帶式眼底攝影機和遠端視網膜評估的使用在島嶼和農村地區尤其普遍。在海灣合作理事會(GCC)國家,糖尿病的高發病率、先進的醫院基礎設施以及國家數位健康策略的共同作用,使得人工智慧驅動的無需散瞳的視網膜成像成為預防保健項目、專科診所和慢性病管理流程中極具吸引力的選擇。
在美國,隨著人們對人工智慧驅動的眼底攝影機分析和遠距離診斷工作流程的理解不斷加深,非散瞳手持式眼底照相機在基層醫療、內分泌科、零售醫療和遠距眼科等領域的糖尿病視網膜病變篩檢應用正在不斷擴展。加拿大幅員遼闊,農村、北部和原住民社區面臨醫療資源匱乏的挑戰,攜帶式視網膜成像技術能夠減輕患者的出行負擔,並促進早期轉診,因此其需求也更加迫切。墨西哥和巴西糖尿病盛行率高,且專科醫生資源分配不均,行動視網膜篩檢和聯網眼底成像正成為公立和私立醫療系統不可或缺的工具。
行業領導者應優先考慮可立即整合到工作流程中的、經過臨床檢驗的解決方案,而不是僅僅在硬體規格上競爭。最有效的策略是將攜帶式、無需散瞳的眼底攝影機與標準化的篩檢方案、操作人員培訓、影像品質保證、安全的雲端連接以及清晰的轉診途徑相結合。設備應針對護理師、基層醫療團隊、糖尿病教育者、驗光師和行動醫療專業人員的易用性進行最佳化,並應具備自動影像擷取功能和即時評估回饋,以減少篩檢失敗。
針對非散瞳手持式眼底攝影機市場趨勢的穩健調查方法,結合了二手資料研究、一手檢驗、技術評估、監管審查和臨床工作流程分析。二手資料研究應參考同儕審查的眼科和糖尿病期刊、公共衛生機構、醫療設備監管資料庫、臨床指南、防盲組織、醫院採購文件、遠距眼科計畫文件以及數位健康政策資訊來源。一手資料研究應包括對眼科醫生、視網膜科醫生、驗光師、內分泌科醫生、基層醫療醫生、糖尿病項目管理人員、放射科醫生、公共衛生管理人員、監管專家和採購相關人員的訪談。
無需散瞳的手持式眼底攝影機正逐漸成為提供便捷視網膜成像的重要工具,尤其是在糖尿病、人口老化和專科醫生短缺等因素導致眼科疾病早期檢測需求日益成長的情況下。當便攜性、無需散瞳成像、與遠距眼科醫療的整合以及人工智慧輔助的分診功能被納入全面的臨床路徑時,其價值才能得到最大程度的發揮。糖尿病高發生率、農村地區醫療資源匱乏、加大對數位醫療投入以及擁有完善的系統性篩檢計畫的地區和國家,尤其能夠從中受益。
The Nonmydriatic Handheld Fundus Cameras Market is projected to grow by USD 164.18 million at a CAGR of 5.99% by 2032.
| KEY MARKET STATISTICS | |
|---|---|
| Base Year [2025] | USD 109.20 million |
| Estimated Year [2026] | USD 118.64 million |
| Forecast Year [2032] | USD 164.18 million |
| CAGR (%) | 5.99% |
Nonmydriatic handheld fundus cameras are reshaping retinal imaging by enabling high-quality fundus photography without routine pharmacologic pupil dilation, supporting faster eye screening in primary care, endocrinology clinics, mobile health programs, emergency departments, pharmacies, and community outreach settings. These portable retinal cameras are increasingly relevant as the global burden of diabetes, hypertension, glaucoma, age-related macular degeneration, and preventable vision impairment continues to rise. Diabetes is a central driver: the International Diabetes Federation reports that 537 million adults were living with diabetes in 2021, while diabetic retinopathy remains one of the leading causes of vision loss among working-age adults. The World Health Organization also identifies unaddressed refractive error, cataract, glaucoma, diabetic retinopathy, and age-related macular degeneration among major contributors to vision impairment. Handheld nonmydriatic retinal imaging helps address this clinical need by improving access to retinal assessment in environments where tabletop fundus cameras, dilated eye examinations, or specialist ophthalmology visits may be difficult to scale.
The technology's appeal lies in portability, noninvasive image capture, lower infrastructure requirements, and suitability for teleophthalmology workflows. When combined with cloud connectivity, electronic health record integration, and artificial intelligence-enabled image triage, handheld fundus cameras can help healthcare systems detect referable retinal disease earlier and improve referral efficiency. Adoption is also supported by public health priorities focused on avoidable blindness, diabetic eye screening, rural healthcare access, and task shifting to trained non-specialist personnel. As a result, nonmydriatic handheld fundus cameras are becoming a strategic tool for decentralized eye care, preventive screening, and digital ophthalmology programs.
The landscape for nonmydriatic handheld fundus cameras is shifting from device-centric adoption toward integrated retinal screening ecosystems. Historically, fundus photography was concentrated in ophthalmology clinics and hospital eye departments with trained imaging technicians and fixed equipment. Current deployment increasingly includes community clinics, pharmacies, diabetes centers, mobile screening units, rural health posts, and home-visit models. This transformation reflects broader healthcare trends: earlier disease detection, decentralized diagnostics, value-based care, chronic disease management, and the use of connected devices to close specialty-care gaps.
Several practical advances are accelerating this shift. Modern handheld fundus cameras are lighter, more ergonomic, and often designed with automated focus, fixation guidance, illumination control, and image quality feedback to improve usability among non-ophthalmic operators. Wireless transfer and cloud-based image storage enable remote grading and asynchronous review, which is essential where ophthalmologists or retinal specialists are scarce. Nonmydriatic capture also reduces patient inconvenience and workflow delays associated with dilation, although smaller pupils, media opacity, cataract, dark irides, and operator technique can still affect image gradability. The result is a maturing digital eye care model in which hardware, software, clinical protocols, and referral pathways must work together to deliver measurable screening impact.
Artificial intelligence is having a cumulative impact on nonmydriatic handheld fundus camera use by improving screening scalability, triage consistency, and workflow productivity. AI-based retinal image analysis has been extensively studied for diabetic retinopathy detection, with multiple peer-reviewed evaluations showing strong diagnostic performance when image quality is adequate and algorithms are validated for the target population. Regulatory-cleared autonomous or assistive AI systems for diabetic retinopathy screening have demonstrated how retinal imaging can be deployed beyond specialist eye clinics, while ongoing research is expanding AI applications into glaucoma risk assessment, macular disease detection, hypertensive retinopathy, cardiovascular risk markers, and image quality assessment.
The most important impact of AI is not simply automation; it is operational leverage. AI can flag ungradable images in real time, prompt recapture, prioritize referable cases, reduce routine manual grading workload, and support standardized documentation. In low-resource or high-volume settings, this can shorten time from image acquisition to referral decision. However, responsible deployment requires rigorous clinical governance. Algorithms must be validated across age groups, ethnicities, camera types, disease prevalence patterns, pupil characteristics, and care settings. Data privacy, cybersecurity, explainability, bias monitoring, medical device regulatory compliance, and clinician oversight remain essential. For industry leaders, AI-enabled handheld fundus imaging should be positioned as a clinically validated screening pathway rather than a standalone diagnostic shortcut.
Asia-Pacific is one of the most important regions for nonmydriatic handheld fundus cameras because it combines large diabetes populations, dense urban health systems, and persistent rural access gaps. China and India carry substantial diabetes and retinal disease burdens, while Japan, South Korea, Australia, and Singapore are advancing digital health infrastructure, aging-care models, and teleophthalmology capabilities. Public screening initiatives, hospital modernization, and expanding chronic disease programs support adoption, but implementation quality varies by reimbursement, workforce training, connectivity, and regional service capacity.
North America shows strong integration potential through established diabetes management pathways, primary care networks, specialty referral systems, and reimbursement mechanisms for remote image interpretation in applicable settings. The United States has been an early adopter of AI-enabled diabetic eye screening, and Canada's geographically dispersed population creates demand for portable retinal imaging in remote, northern, and Indigenous communities. Latin America is advancing through diabetes screening programs, private healthcare adoption, and mobile health initiatives, particularly in Brazil and Mexico, while unequal specialist distribution and budget constraints make portable nonmydriatic systems relevant for expanding access to retinal assessment.
Europe benefits from structured healthcare systems, national or regional diabetic eye screening programs, and strong regulatory emphasis on medical device safety, data protection, and clinical evidence. Western European countries are focused on integration with established screening services, while parts of Central and Eastern Europe present opportunities tied to modernization and rural access. In the Middle East, high diabetes prevalence and investment in digital healthcare are driving interest in retinal screening across Gulf health systems, with opportunities in hospital networks, preventive care, and premium outpatient services. Africa presents a critical access-driven opportunity: limited ophthalmology workforce density, growing noncommunicable disease prevalence, and large rural populations support the case for handheld fundus cameras, especially when paired with teleophthalmology, training programs, reliable connectivity, and sustainable public-private service models.
ASEAN countries are increasingly relevant for nonmydriatic handheld fundus cameras as governments expand universal health coverage, diabetes care, and community-level screening. Urban hospitals in Singapore, Malaysia, Thailand, Indonesia, Vietnam, and the Philippines are strengthening digital diagnostics, while archipelagic and rural geographies create a strong use case for portable fundus photography and remote retinal grading. GCC countries are influenced by high diabetes prevalence, advanced hospital infrastructure, and national digital health strategies, making AI-enabled nonmydriatic retinal imaging attractive for preventive care programs, specialist clinics, and chronic disease management pathways.
The European Union emphasizes regulated adoption, interoperability, data protection, and evidence-based screening. The EU's focus on medical device compliance, digital health standards, and privacy-by-design implementation supports high-quality deployment, although procurement processes and country-specific screening models shape adoption speed. BRICS economies combine large patient populations, expanding healthcare infrastructure, and uneven access to ophthalmology specialists. Brazil, Russia, India, China, and South Africa therefore represent diverse opportunities for portable retinal screening in public health, private care, and telemedicine networks, provided affordability, training, connectivity, and local clinical validation are addressed.
G7 countries generally have stronger reimbursement structures, digital health maturity, and specialist networks, which support integration of handheld fundus cameras into chronic disease care, aging population management, and AI-assisted screening workflows. NATO countries overlap significantly with North America and Europe, where defense and public health systems may also value rugged, portable diagnostic tools for deployed care, remote clinics, humanitarian response, and emergency preparedness. Across all groups, the decisive adoption factors are clinical validation, workflow fit, data security, device usability, and the ability to generate actionable referrals rather than images alone.
The United States is advancing nonmydriatic handheld fundus camera adoption through diabetic retinopathy screening in primary care, endocrinology, retail health, and teleophthalmology settings, supported by growing familiarity with AI-based retinal analysis and remote interpretation workflows. Canada's needs are shaped by vast geography and access challenges in rural, northern, and Indigenous communities, where portable retinal imaging can reduce travel burdens and support earlier referral. Mexico and Brazil face large diabetes populations and unequal specialist access, making mobile retinal screening and connected fundus photography important tools for public and private health systems.
In Europe, the United Kingdom benefits from mature diabetic eye screening experience and an established culture of retinal image grading, creating a favorable environment for portable imaging when it improves reach and efficiency. Germany emphasizes regulated medical technology adoption, hospital quality standards, and specialist-led care, while France supports innovation through structured healthcare delivery and digital health initiatives. Italy and Spain face aging populations and high chronic disease needs, making nonmydriatic fundus cameras useful for community screening, ophthalmology networks, and telemedicine. Russia's large geography and regional access disparities create demand for portable imaging solutions that can support outreach, remote consultation, and chronic disease monitoring.
China has a major opportunity due to its large diabetes population, expanding hospital infrastructure, and rapid digital health adoption, while India's high diabetes burden, rural population distribution, and shortage of eye care specialists make handheld nonmydriatic cameras especially relevant for scalable screening. Japan's aging society and advanced medical device environment support use in chronic eye disease monitoring and community care. Australia's remote population challenges, including access needs in regional and Aboriginal and Torres Strait Islander communities, align well with portable teleophthalmology-enabled imaging. South Korea's connected healthcare infrastructure, technology adoption, and strong hospital systems support integration of handheld fundus cameras into preventive retinal screening and digital ophthalmology workflows.
Industry leaders should prioritize clinically validated, workflow-ready solutions rather than competing on hardware specifications alone. The strongest strategies include pairing handheld nonmydriatic fundus cameras with standardized screening protocols, operator training, image quality assurance, secure cloud connectivity, and clear referral pathways. Devices should be optimized for ease of use by nurses, primary care teams, diabetes educators, optometrists, and mobile health workers, with automated image capture support and real-time gradability feedback to reduce failed screenings.
AI integration should be evidence-led. Leaders should validate algorithms on images captured with the intended camera model, across diverse populations and disease severities, and under real-world clinical conditions. Regulatory alignment, cybersecurity safeguards, patient consent management, and audit trails should be built into product and service design. Partnerships with diabetes clinics, public health programs, hospitals, insurers, and teleophthalmology networks can improve deployment success. In emerging markets, affordability, durability, multilingual user interfaces, offline functionality, rechargeable power performance, and local service support are critical. In mature markets, interoperability with electronic health records, reimbursement documentation, quality reporting, and population health analytics will be decisive differentiators.
A robust research methodology for the nonmydriatic handheld fundus cameras landscape combines secondary research, primary validation, technology assessment, regulatory review, and clinical workflow analysis. Secondary research should draw from peer-reviewed ophthalmology and diabetes journals, public health agencies, medical device regulatory databases, clinical guidelines, blindness prevention organizations, hospital procurement materials, teleophthalmology program documentation, and digital health policy sources. Primary research should include interviews with ophthalmologists, retina specialists, optometrists, endocrinologists, primary care physicians, diabetes program managers, imaging technicians, public health administrators, regulatory specialists, and procurement stakeholders.
The analysis should evaluate device usability, portability, field of view, image resolution, nonmydriatic performance, battery life, connectivity, infection control design, data management, AI compatibility, and integration with clinical workflows. Evidence review should distinguish between screening, diagnostic, and monitoring use cases, while also assessing image gradability, sensitivity and specificity where published, referral outcomes, operator training requirements, and real-world implementation barriers. Regional and country-level insights should be interpreted through healthcare access, disease burden, reimbursement, regulatory requirements, digital infrastructure, workforce availability, and public health priorities. This evidence-led methodology ensures conclusions are grounded in verified sources and operational relevance.
Nonmydriatic handheld fundus cameras are becoming a critical enabler of accessible retinal imaging, particularly as diabetes, aging populations, and specialist shortages intensify demand for earlier detection of eye disease. Their value is strongest when portability, nonmydriatic image capture, teleophthalmology connectivity, and AI-supported triage are combined into a complete clinical pathway. Regions and countries with high diabetes prevalence, rural access constraints, digital health investment, and structured screening programs are especially well positioned to benefit.
Future success will depend on more than device deployment. Industry stakeholders must demonstrate clinical reliability, integrate with healthcare workflows, protect patient data, support diverse care settings, and ensure that screening results lead to timely referral and treatment. With responsible AI implementation, strong training models, and evidence-based partnerships, nonmydriatic handheld fundus cameras can help expand preventive eye care and reduce avoidable vision loss across both mature and emerging healthcare systems.